New drugs: pitavastatin calcium, vigabatrin, and romidepsin.

@article{Hussar2010NewDP,
  title={New drugs: pitavastatin calcium, vigabatrin, and romidepsin.},
  author={Daniel A. Hussar and M. Christian},
  journal={Journal of the American Pharmacists Association : JAPhA},
  year={2010},
  volume={50 4},
  pages={
          548-51
        }
}
Lipid-regulating agent Pitavastatin calcium (Livalo—Kowa; Lilly) is the eighth 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) to be marketed in the United States, joining atorvastatin (Lipitor), fluvastatin (e.g., Lescol XL), lovastatin, pravastatin, rosuvastatin (Crestor), and simvastatin. Cerivastatin (Baycol) was marketed from 1998 to 2001 but was withdrawn from the market because of concern regarding serious adverse events (i.e., myopathy, rhabdomyolysis). Like the other… Expand
2 Citations
Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma
TLDR
Romidepsin is an effective, durable, and well-tolerated single-agent therapy in patients with refractory CTCL and should be considered for formulary addition in this population. Expand
Pitavastatin up‐regulates eNOS production by suppressing miR‐155 expression in lipopolysaccharide‐stimulated human umbilical vein endothelial cells
TLDR
Pitavastatin ameliorated LPS-induced endothelial dysfunction through upregulation of eNOS expression and downregulation of miR-155 expression as revealed by RT-PCR and Western blotting. Expand